Long-term @entity10042 treatment for XXXX : clinical efficacy and influence on gastric mucosa.

@entity1 @entity4726 @entity5 @entity10042 @entity194 @entity354 @entity1534 @entity3621
BACKGROUND: Long-term acid suppression is believed to accelerate @entity4726 in @entity1534 -positive @entity1 . The influence of long-term therapy with @entity10042 has not been examined. AIM: To study the clinical and endoscopic efficacy and histological evolution of gastric mucosa during 5 years of maintenance treatment with @entity10042 , 30 mg. METHODS: Seventy-eight @entity1 with endoscopically proven @entity354 were followed for 5 years. Biopsies taken at the start of the study, during follow-up and after 5 years were available for 73 @entity1 . RESULTS: The total endoscopic relapse rate was 14.1%. At the start of the study, 34 @entity1 were @entity1534 negative and 39 were @entity1534 positive (two @entity194 , 25 antral @entity3621 , 12 pangastritis). At 5 years, no histological changes had occurred in @entity1534 -negative @entity1 . In the @entity1534 -positive group, 20 @entity1 developed pangastritis, six had normal histology and one had antral @entity3621 . Ten of the 12 @entity1 with pangastritis had reduced antral activity. There was no increase in intestinal metaplasia, but there was a tendency towards regression of @entity194 in the antrum and towards increased @entity194 in the body of the stomach. CONCLUSIONS: Maintenance treatment with @entity10042 , 30 mg, is efficacious. The development of @entity194 and intestinal metaplasia was not accelerated in @entity1534 -positive @entity1 . @entity1534 eradication must be considered only because of the higher @entity5 risk associated with chronic @entity1534 -related @entity3621 .
